Trius Therapeutics to Present Data From Antibiotic Drug Development Programs at ICAAC

SAN DIEGO, Sept. 14, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate tedizolid phosphate (formerly known as torezolid phosphate and TR-701), will be presented in poster and slide presentations at the 51th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Chicago September 17-20. In addition to the results of clinical and nonclinical studies of tedizolid phosphate, the posters highlight advances in Trius' preclinical GyrB antibacterial program that is targeting gram-negative pathogens, a class of bacteria rapidly developing resistance to existing antibiotics and for which there are few new antibiotics in development.

The presentations are as follows:

Saturday, September 17th

Poster Presentations 005 — Pharmacokinetic/Pharmacodynamic (PK/PD) of New Antibacterial Agents (11:30 a.m. — 1:30 p.m.)

- A2-033: An Evaluation Of The Absorption, Metabolism, And Excretion Of Orally Administered [^{14}C]-TR-701 FA In Healthy Subjects; H. Dreskin, T. Boyea, J. Barker, E. Fang, P. Prokocimer

Sunday, September 18th

Poster Presentation 091 — Conventional Methods for Antimicrobial Susceptibility Testing (11:15 a.m. — 1:15 p.m.)

- D-688: Establishment of Quality Control Ranges for Testing the Susceptibility of Target Organisms to TR-700 by Disk Diffusion; J. Deane, C. Pillar, D. Sahm, K. Bartizal

Slide Presentation 113 — Staphylococci: Novel Environments and Novel Mechanisms of Resistance (1:30 p.m. — 4:00 p.m.)

- C2-945: In Vitro Activity of Tedizolid (TR-700) Against Linezolid-Resistant Gram-positive Clinical Isolates Possessing the cfr Methyltransferase Gene and/or Ribosomal Gene Mutations; E. Cercenado, M. Marín, B. Gama, C. Iglesias, E. Bouza

Monday, September 19th

Poster Presentations 194 — Management Issues in Skin and Soft Tissue Infections (11:15 a.m. — 1:15 p.m.)

- L1-1494: Correlation between Digital Planimetry and a Traditional Manual Method in the Measurement of Lesion Size in a Phase 3 Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Study; P. Bien , C. De Anda, E. Fang, P. Prokocimer

- L1-1496: Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Dose-Ranging Phase 2 Tedizolid Phosphate (TR-701) Study: Assessment of Efficacy with New FDA Guidance; C. De Anda, A. Das, E. Fang, P. Prokocimer

Poster Presentations 176 — Gram-Positive Antimicrobials (11:15 a.m. — 1:15 p.m.)

- E-1324: Comparative Potency of Oxazolidinones Tedizolid (TR-700) and Linezolid Against Target Gram-Positive Pathogens in the US from 2009-2010; C. Pillar, D. Sahm, K. Bartizal

Poster Presentations 177 —*Staphylococcus* (11:15 a.m. — 1:15 p.m.)

- E-1342: Activity of Tedizolid (TR-700) Against Well-characterized MRSA Strains of Diverse Epidemiological Origin; K. Thomson, J. Kum, R. Goering

Tuesday, September 20th

Poster Presentations 237 — Penetration of Anti-Infective Agents and PK/PD Modeling Issues (9:00 a.m. — 11:00 a.m.)

- A1-1746: Pharmacokinetics and Pulmonary Disposition of Tedizolid and Linezolid in Three Murine Models; R. Keel, J. Crando, D. Nicolau
- A1-1747: Pulmonary Disposition of Tedizolid Following 200 mg Once-Daily Oral Tedizolid Phosphate in Healthy Volunteers; S. Housman, J. Pope, J. Russomanno, E. Salerno, E. Shore, J. Kuti, D. Nicolau

Poster Presentations 247 — Structure-Based Drug Design (9:00 a.m. — 11:00 a.m.)

- F1-1837: The Discovery of Potent, Dual Targeting Pyrrolopyrimidine Inhibitors of Bacterial DNA Gyrase B and Topoisomerase IV with Broad Spectrum Antibacterial Activity; L. Tari, D. Bensen, M. Trzoss, T. Lam, J. Zhang, X. Li, Z. Chen, C. Creighton, M. Cunningham, B. Kwan, K. Nelson, A. Castellano, M. Stidham, V. Brown-Driver, F. Lightstone, S. Wong, T. Nguyen, K. Shaw, J Finn
- F2-1872: The Discovery of Novel, Dual Targeting Inhibitors of Bacterial DNA Gyrase B and Topoisomerase IV using Pharmacophore-Based Crystallographic Fragment Screening; L. Tari, D. Bensen, M. Trzoss, T. Lam, J. Zhang, X. Li, Z. Chen, C. Creighton, M. Cunningham, B. Kwan, K. Nelson, A. Castellano, M. Stidham, V. Brown-Driver, F. Lightstone, S. Wong, K. Shaw, J. Finn

Copies of these posters will be available on the Trius website following the ICAAC meeting: http://www.triusrx.com/trius-therapeutics-news-posters-publications-year.php.

About Trius Therapeutics

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. The company's lead investigational drug, tedizolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of ABSSSI. Trius has two Special Protocol Assessments (SPA) with the FDA for its two Phase 3 ABSSSI trials and has partnered with Bayer HealthCare for the development and commercialization of tedizolid phosphate outside of the U.S. and the European Union. In addition to the company's tedizolid phosphate clinical program, Trius is currently conducting three preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit www.triusrx.com.

CONTACT: Public Relations Contact:

Jason Spark at Canale Communications, Inc.

jason@canalecomm.com

619-849-6005

Investor Relations Contact:

Stefan Loren at Westwicke Partners, LLC

sloren@westwicke.com

443-213-0507